Home FOR AUTHORS Bratislava Medical Journal 2024 Bratislava Medical Journal Vol.125, No.3, p. 166–171, 2024

Journal info


 


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.5

 

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.125, No.3, p. 166–171, 2024

Title: Characterization of HIV-1 subtypes and drug resistance mutations in Slovakia: update 2017–2018
Author: Monika HABEKOVA, Danica VALKOVICOVA STANEKOVA, Maria TAKACOVA, Alexandra KOVAROVA

Abstract: OBJECTIVES: This study aimed to provide an overview on the HIV-1 subtypes circulating in Slovakia between 2017 and 2018 and to evaluate the risk of transmission of HIV‑resistant strains.
BACKGROUND: The HIV epidemic in Slovakia is characterised by low incidence of new and pre-existing infections and a slightly elevated level of strain heterogeneity.
METHODS: Partial HIV pol gene sequences of 110 individuals newly diagnosed with HIV between 2017 and 2018 were analysed.
RESULTS: The genotypic analysis revealed sporadic occurrence of mutations linked to HIV resistance to antiretroviral therapy (ART). The HIV-1 B subtype has been found as predominant (84.55 %) and primarily linked to men who have sex with men (MSM). A total of eighteen individuals (15.45 %) were found to be infected with HIV-1 non-B subtypes.
CONCLUSION: The data suggest a minimal risk of a resistant HIV strain transmission and a marginal rise of HIV-1 subtypes´ diversity. The HIV-1 B subtype remains the most prevalent in the period 2017–2018 in Slovakia (Tab. 2, Fig. 2, Ref. 37).

Keywords: HIV-1, subtypes, Slovakia, resistance, ART
Published online: 27-Dec-2023
Year: 2024, Volume: 125, Issue: 3 Page From: 166, Page To: 171
doi:10.4149/BLL_2024_26


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.